Advances and Future Expectations in Oncolytic Virus Therapy for Glioblastoma: A Systematic Review of Clinical Trials.

Overview

1. Faculty of Medicine, Tishreen University, Lattakia, Syrian Arab Republic
2. Cancer Research Center, Tishreen University, Lattakia, Syrian Arab Republic
3. Faculty of Medicine, Al Andalus University for Medical Sciences, Tartus, Syria
4. Division of Oncology, Department of Medicine, Washington University School of Medicine in Saint Louis, Washington, USA
5. Department of Pathology, Tishreen University Hospital, Lattakia, Syrian Arab Republic

Abstract

Background: Glioblastoma (GB), or grade IV astrocytoma, is the most prevalent primary tumor of the central nervous system (CNS). This systematic review aimed to investigate the efficacy and tolerability of virotherapy treatment for recurrent and progressive glioblastoma patients. We also examined recent progress in preclinical and clinical trials, and future perspectives.

Methods: We developed a search strategy using Medical Subject Headings (MeSH) terms and keywords. Inclusion criteria were English language published and ongoing clinical trials that involved patients undergoing virotherapy for glioblastoma. We searched through PubMed, Embase, Ovid, Scopus, Cochrane databases and https://Clinicaltrials.gov from inception until May 9th, 2025. Two independent reviewers screened records, extracted data, and assessed risk of bias (ROB2). No meta-analysis was performed due to heterogeneity. PROSPERO CRD420250636791.

Results: Of 975 records screened, 43 studies (24 published, 19 ongoing) enrolled 462 virotherapy patients. Most common adverse events: headache (n=145), fatigue (n=83) and fever (n=78). Risk of bias was moderate to serious in most studies.

Conclusion: We encountered several limitations, including high heterogeneity, reporting inconsistencies, and small sample sizes. Most patients experienced disease stabilization. However, objective response and complete remission occurred infrequently. A small proportion of patients achieved long-term survival, suggesting that virotherapy could be effective in specific subgroups. While oncolytic virus therapy is generally tolerated, neurotoxicity remains the most significant risk. Adverse effects were mostly Grade 1–2. Some trials (notably with HSV-1 or NDV) had severe events. Symptoms were often transient and manageable but need closely monitoring. However, the observed heterogeneity, limited data standardisation, and lack of randomized controlled trials, besides tumor heterogeneity, antiviral immunity and immunosuppressive microenvironment, necessitate further research to identify predictive biomarkers and optimize therapeutic protocols. We also suggest further trials on novel delivery methods, such as the nanoparticles, to enhance blood-brain barrier (BBB) penetration.

Reproduced under the paper's license (CC BY-NC), from the paper cited above.

Code

The paper says that its authors' code is available on request: it was not published with the paper, so there is nothing to verify.

The paper's code and data availability statement is in the Data section.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none (its code is available on request), so it has no map.

Data

No dataset and no data link were found in the paper.

Data Availability Statement

The data is available from the corresponding author upon reasonable request. The data extraction forms are provided as Supplementary File. Extracted data and analytic code are available from the corresponding author.*

Reproduced under the paper's license (CC BY-NC), from the paper cited above.

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 1, 27 September 2026: the first record

Recorded: type, language, journal, volume, pages, dates, 9 authors, 7 keywords, 64 references.

Cite

This paper

Kenaan, N., Bashour, G., Kheyrbek, N., Haddad, S., Sardini, M., Sabbagh, M., Hannouneh, Z. A., Ansstas, G., & Alshehabi, Z. (2026). Advances and Future Expectations in Oncolytic Virus Therapy for Glioblastoma: A Systematic Review of Clinical Trials. Clinical Medicine Insights. Oncology, 20, 11795549261466431. https://doi.org/10.1177/11795549261466431

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.1016/j.omton.2026.201263

Comparative evaluation of oncolytic viruses reveals opposing preferences for glioblastoma subtypes.

Journal: Molecular therapy. Oncology

In common: other condition, 7 references

[2] doi:10.1016/j.omton.2026.201201

Enable CAR T cell immunotherapy in glioblastoma by modifying its microenvironment via oncolytic adenovirus encoding bispecific T cell engager.

Journal: Molecular therapy. Oncology

In common: other condition, 3 references

[3] doi:10.3390/biomedicines14071628

Circulating Placental Growth Factor as a Prognostic Biomarker in High-Risk Glioblastoma Patients.

Journal: Biomedicines

In common: clinical / translational, other condition, 1 reference

[4] doi:10.1186/s12974-026-03964-3

Circulating immune profiling reveals impaired monocyte states and trajectories driving immunosuppression in glioblastoma.

Journal: Journal of neuroinflammation

In common: clinical / translational, other condition, 1 reference

[5] doi:10.1038/s41586-026-10329-6 [code]

Synthetic super-enhancers enable precision viral immunotherapy.

Journal: Nature

In common: other condition, 1 reference

[6] doi:10.1038/s41598-026-53415-5 [code]

Computational design and immunoinformatics validation of a T cell multi-epitope vaccine targeting glioblastoma stem cells.

Journal: Scientific reports

In common: other condition, 1 reference

[7] doi:10.1128/jvi.00208-26

MicroRNA-124-targeted recombinant Zika virus: a dual-functional and safe candidate for vaccination and oncolytic virotherapy.

Journal: Journal of virology

In common: other condition, 1 reference

[8] doi:10.3390/biomedicines14081702 [code]

Complement-Targeted Therapies in Glioblastoma: A Systematic Review.

Journal: Biomedicines

In common: clinical / translational, other condition, 1 reference

[9] doi:10.4103/joacp.joacp_734_25

Awake craniotomy for brain tumors during pregnancy: An updated scoping review.

Journal: Journal of anaesthesiology, clinical pharmacology

In common: clinical / translational, other condition, 1 reference

[10] doi:10.3389/fimmu.2026.1866830

Heterogeneity of immune checkpoint inhibitor-related inflammatory central nervous system adverse event reporting signals in primary and metastatic brain tumors: a pharmacovigilance study with single-cell and spatial transcriptomic contextualization.

Journal: Frontiers in immunology

In common: other condition, 1 reference

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion: questions and error reports about this paper and its code, from signed-in readers and its authors. It opens with sign-in.

Reproductions: reports from readers who ran the authors' code: what they reproduced, with which environment, commit and data. It opens with sign-in.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.